Cul4B up‐regulation attenuates sepsis‐induced acute lung injury by promoting NLRP3 ubiquitination and inhibiting NLRP3 inflammasome activation
British Journal of Pharmacology · 2026-12 · 183 (23) · 6801-6823
DOI: 10.1111/bph.70605 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 16.08.2026. Verfasst von Huihui Hu und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment; Guangdong Basic Research Center of Excellence for Natural Bioactive Molecule…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Acute Lung Injury, Cullin Proteins, Sepsis. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Key Research Project, Natural Science Foundation of Guangdong province.
Themen: Sepsis
Abstract (Originalsprache)
Background and Purpose Cullin 4B (Cul4B), a scaffold protein of CUL4B‐RING E3 ligase complex, functions primarily as a negative regulator of inflammation. This study aims to investigate its role in acute lung injury (ALI) and NLRP3 ubiquitination. Experimental approach Cul4B expression and distribution were examined in two sepsis‐induced ALI mouse models. Lung‐specific overexpression and myeloid‐specific Cul4B deletion were applied to evaluate its effects on lung histopathology, pulmonary inflammation, and alveolar capillary barrier dysfunction. The role of Cul4B in NLRP3 inflammasome activation was evaluated in THP‐1 cells and Cul4B‐deficient BMDMs. Cul4B‐NLRP3 interaction and Cul4B‐mediated NLRP3 ubiquitination were determined. The involvement of Cul4B in MN‐08‐mediated ALI protection and inflammasome suppression was also investigated. Key results Cul4B was significantly downregulated in lung tissues of sepsis‐induced ALI mice. Pulmonary overexpression of Cul4B attenuated lung injury and inflammation, whereas myeloid‐specific deletion of Cul4B exacerbated epithelial barrier damage and inflammatory responses, along with enhanced Nigericin‐induced NLRP3 inflammasome activation. Cul4B was shown to interact with both endogenous and exogenous NLRP3 and suppressed NLRP3 inflammasome activation by promoting NLRP3 ubiquitination. MN‐08, a small molecule previously reported to alleviate lipopolysaccharide (LPS)‐induced ALI, was found to upregulate Cul4B expression and inhibit NLRP3 inflammasome activation by promoting NLRP3 ubiquitination. Conclusions and implications Upregulating Cul4B promotes NLRP3 ubiquitination, thereby inhibiting inflammasome activation and mitigating pulmonary epithelial barrier dysfunction and inflammation in ALI. Cul4B emerges as a potential therapeutic target, and these findings provide new insights into the mechanism by which MN‐08 protects against sepsis‐induced ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment; Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan Univer…
- Department of Intensive Care Unit, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
- Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases; Institute of New Drug Research, College of Pharmacy, Jinan University, Guangzhou 510632, China.
- Department of Microbiology and Immunology, Health Science Center, School of Medicine, Jinan University, Guangzhou 510632, China.
- Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China.
- Guangzhou Magpie Pharmaceuticals Co., Ltd., Guangzhou 510700, China.
ORCID-Profile: Huihui Hu, Zaijun Zhang
Förderung
- National Natural Science Foundation of China
- Guangzhou Key Research Project
- Natural Science Foundation of Guangdong province
- Science and Technology Projects in Guangzhou
- Fundamental Research Funds for the Central Universities
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University
- Medical Scientific Research Foundation of Guangdong Province
Zitieren
APA
Hu, H., Wang, J., Zhang, Y., Yao, C., Zhao, F., Yuan, X., Zhang, F., Xiang, Z., Cui, G., Jing, M., Yi, P., Sun, Y., Zhang, G., Wang, Y., Yin, H. Y., Zhang, Z., & Gu, W. J. (2026). Cul4B up‐regulation attenuates sepsis‐induced acute lung injury by promoting NLRP3 ubiquitination and inhibiting NLRP3 inflammasome activation. British Journal of Pharmacology, 183(23), 6801-6823. https://doi.org/10.1111/bph.70605
Vancouver
Hu H, Wang J, Zhang Y, Yao C, Zhao F, Yuan X, et al. Cul4B up‐regulation attenuates sepsis‐induced acute lung injury by promoting NLRP3 ubiquitination and inhibiting NLRP3 inflammasome activation. British Journal of Pharmacology. 2026;183(23):6801-6823. doi:10.1111/bph.70605
BibTeX
@article{Hu2026,
author = {Hu, Huihui and Wang, Jiabei and Zhang, Yuqing and Yao, Chuanjie and Zhao, Fengzhi and Yuan, Xiangkun and Zhang, Feng and Xiang, Zheng and Cui, Guozhen and Jing, Mei and Yi, Peng and Sun, Yewei and Zhang, Gaoxiao and Wang, Yuqiang and Yin, Hai-Yan and Zhang, Zaijun and Gu, Wan-Jie},
title = {Cul4B up‐regulation attenuates sepsis‐induced acute lung injury by promoting NLRP3 ubiquitination and inhibiting NLRP3 inflammasome activation},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {23},
pages = {6801--6823},
doi = {10.1111/bph.70605}
}
EUVIMED